Veracyte has been generating cash for R&D and striking deals to expand its market reach. Now, the company is touting promising results for its bronchial genomic classifier for lung cancer diagnosis as it takes a deeper dive into the lung cancer testing market.
UCSD researchers have developed a hydrogel that contains toxin-absorbing nanoparticles--what they are calling nanosponges--that could eventually treat skin and wound conditions caused by methicillin-resistant Staphylococcus aureus, or MRSA.
Endo Pharmaceuticals and BioDelivery Sciences International announced positive results from two Phase III studies of their Belbuca buccal film to manage severe chronic pain by quickly delivering buprenorphine via the inside of the cheek. The candidate uses BDSI's BioErodible MucoAdhesive delivery platform.
PatientsLikeMe has lured Jason Johnson away from Merck. Johnson is leaving Merck after 14 years at the Big Pharma to head up R&D at PatientsLikeMe, a role which gives him responsibility for efforts to extract insights from patient-reported data.
Israel has become the latest country to disclose plans to create a population-scale database of linked genetic and clinical records. The current plan is reminiscent of the United Kingdom's 100,000 Genomes Project, with Israel considering working with tech firms to create a database of patients with rare genetic diseases.
Sorrento Therapeutics, a frequent partner of billionaire biotech entrepreneur Patrick Soon-Shiong, launched a new subsidiary to advance its take on CAR-T therapies for cancer, taking a page from its patron as it tosses more and more irons in the R&D fire.
Medtronic is touting positive study results for its antibacterial envelope in high-risk patients who undergo cardiac device implantation, a feather in the company's cap as it continues to forge ahead with the innovative technology.
St. Jude Medical said in a new study that its CardioMEMS HF System can deliver improved outcomes and be cost-effective for heart failure patients who are already well-managed for their condition when they use pulmonary artery pressure monitoring.
The commercial potential of NASH, a common liver disease with no approved treatments, has seemingly launched a thousand R&D ships around the industry. And Novo Nordisk, emboldened by an investigator-sponsored study, might be sitting on an effective therapy for the pervasive ailment with liraglutide, a blockbuster already approved for diabetes and obesity.
Celgene's expansive approach to partnering continues to bear fruit, as two of the Big Biotech's in-licensed treatments have been added to the FDA's fast-track program, promising a speedy regulatory review as each approaches Phase III.